Drug Discovery World

AUGUST 20, 2024

Mirit Eldor , Managing Director, Life Sciences Solutions, Elsevier, looks at how artificial intelligence (AI) can improve the hit-to-lead process for small molecules. It’s therefore no surprise that pharmaceutical companies are increasingly interested in using artificial intelligence (AI) to accelerate development and reduce costs.

Small Molecule 275

Small Molecule Pharmaceutical Companies Drugs Pharmaceuticals 275

Drug Discovery World

SEPTEMBER 26, 2022

It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Diving into data .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 X H NMR (500 MHz, DMSO-i¾) δ ppm 1.40 (d, J=6.8 88 (8): 3872–3882.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

JANUARY 19, 2021

Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. About ALS-4. About Aptorum Group.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Genkyotex SA , a subsidiary of Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX; NASDAQ – CALT), today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex’s lead asset. STOCKHOLM , Jan.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

Practical Cheminformatics

JANUARY 8, 2024

In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. These information retrieval capabilities have many applications, from writing computer code and collating clinical trial results to summarizing papers on a specific topic.

Drugs 141

Drugs Small Molecule Packaging Bioinformatics 141

Agency IQ

FEBRUARY 23, 2024

On the first day, discussants looked at how to tackle first-in human trials, weighed the importance of the maximum tolerated dose, and looked at the evolving concept of the clinical utility index. This has spawned a movement focused on optimizing dose selection in oncology drug development.

Science 40

Science FDA Trials Clinical Pharmacology 40